Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. Partnership to develop haemophilia gene therapy
  2. Breaking cancer’s drug addiction
  3. Merck to develop oncology drugs with Cancer Research UK and ICR
  4. Sanofi and Regeneron’s Kevzara faces competition in rheumatoid arthritis market
  5. Batavia Biosciences joins project to develop new polio vaccine

Latest Content

The Nymi™ Band

This white paper provides the reader with an overview of the Nymi Band™ and how it works. 

Breaking cancer’s drug addiction

Cancer cells can become addicted to the drugs designed to kill them, and now a group of scientists from the Netherlands Cancer Institute has discovered the underlying mechanism. Abi Millar finds out why cells die en masse when treatment is removed and how this could be exploited in a clinical setting.

Sanofi and Regeneron’s Kevzara faces competition in rheumatoid arthritis market

At the 36th annual J.P. Morgan Healthcare Conference, Sanofi and Regeneron discussed the anticipated success of Kevzara (sarilumab), an interleukin 6 (IL-6) inhibitor approved in 2017 for moderate to severely active rheumatoid arthritis (RA) patients with an inadequate response or intolerance to at least one disease-modifying anti-rheumatic drug (DMARD).

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top